FDA Approved: TAVNEOS — Supplemental Application (ChemoCentryx, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TAVNEOS (avacopan) submitted by ChemoCentryx, expanding its regulatory status for the treatment of ANCA-associat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• TAVNEOS (avacopan)

Snippet

SUPPL AP for TAVNEOS (AVACOPAN)